La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

DexCom Gestion

Gestion contrôle des critères 4/4

Le PDG DexCom's est Kevin Sayer, nommé en Jun2011, a un mandat de 13.17 ans. La rémunération annuelle totale est $ 15.71M, composée du salaire de 7% et des bonus 93%, y compris les actions et options de la société. détient directement 0.043% des actions de la société, d'une valeur de $ 13.01M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.6 ans et 8.6 ans.

Informations clés

Kevin Sayer

Directeur général

US$15.7m

Rémunération totale

Pourcentage du salaire du PDG	7.0%
Durée du mandat du directeur général	13.3yrs
Propriété du PDG	0.04%
Durée moyenne d'occupation des postes de direction	2.7yrs
Durée moyenne du mandat des membres du conseil d'administration	8.7yrs

Mises à jour récentes de la gestion

Recent updates

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

May 16

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

Mar 21

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Mar 03

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Feb 13

DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Nov 25

Analyse de la rémunération des PDG

Comment la rémunération de Kevin Sayer a-t-elle évolué par rapport aux bénéfices de DexCom?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	US$667m
Mar 31 2024	n/a	n/a	US$639m
Dec 31 2023	US$16m	US$1m	US$542m
Sep 30 2023	n/a	n/a	US$377m
Jun 30 2023	n/a	n/a	US$358m
Mar 31 2023	n/a	n/a	US$293m
Dec 31 2022	US$15m	US$953k	US$341m
Sep 30 2022	n/a	n/a	US$244m
Jun 30 2022	n/a	n/a	US$230m
Mar 31 2022	n/a	n/a	US$258m
Dec 31 2021	US$12m	US$900k	US$217m
Sep 30 2021	n/a	n/a	US$577m
Jun 30 2021	n/a	n/a	US$562m
Mar 31 2021	n/a	n/a	US$530m
Dec 31 2020	US$14m	US$800k	US$550m
Sep 30 2020	n/a	n/a	US$231m
Jun 30 2020	n/a	n/a	US$205m
Mar 31 2020	n/a	n/a	US$148m
Dec 31 2019	US$10m	US$691k	US$101m
Sep 30 2019	n/a	n/a	-US$171m
Jun 30 2019	n/a	n/a	-US$170m
Mar 31 2019	n/a	n/a	-US$130m
Dec 31 2018	US$10m	US$601k	-US$127m
Sep 30 2018	n/a	n/a	US$43m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$33m
Dec 31 2017	US$8m	US$546k	-US$50m

Rémunération vs marché: La rémunération totale de Kevin ($USD 15.71M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 13.21M ).

Rémunération et revenus: La rémunération de Kevin a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Kevin Sayer (66 yo)

13.3yrs

Titularisation

US$15,712,244

Compensation

Mr. Kevin Ronald Sayer has been Executive Chairman of DexCom, Inc. since July 30, 2018. Mr. Sayer has been the Chief Executive Officer of DexCom, Inc. since January 5, 2015 and as its President since June...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Kevin Sayer	Executive Chairman	13.3yrs	US$15.71m	0.043% $ 11.7m
Jereme Sylvain	Executive VP	4.5yrs	US$4.25m	0.0088% $ 2.4m
Jacob Leach	Executive VP & COO	2.1yrs	US$4.94m	0.065% $ 17.4m
Michael Brown	Executive VP & Chief Legal Officer	2.7yrs	US$4.34m	0.0013% $ 358.6k
Teri Lawver	Executive VP & Chief Commercial Officer	1.7yrs	US$6.53m	0.0016% $ 442.2k
Girish Naganathan	Executive VP & CTO	1.9yrs	US$4.05m	0.0013% $ 361.3k
Stacey Stewart	Senior VP & Chief Information Officer	less than a year	pas de données	pas de données
Sean Christensen	Director of Corporate Affairs & Head of Investor Relations	no data	pas de données	pas de données
Matthew Dolan	Executive Vice President of Strategy	3.5yrs	pas de données	0% $ 0
Leverne Marsh	Executive Vice President of Marketing	less than a year	pas de données	pas de données
Sadie Stern	Executive VP & Chief Human Resources Officer	4yrs	pas de données	0.0058% $ 1.6m
Steven Pacelli	Executive VP & MD of Dexcom Ventures	3.4yrs	US$3.02m	0.021% $ 5.8m

2.7yrs

Durée moyenne de l'emploi

49yo

Âge moyen

Gestion expérimentée: L'équipe de direction de DXCM est considérée comme expérimentée (ancienneté moyenne 2.6 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Kevin Sayer	Executive Chairman	16.8yrs	US$15.71m	0.043% $ 11.7m
Mark Foletta	Lead Independent Director	9.8yrs	US$393.51k	0.014% $ 3.8m
Steven Altman	Independent Director	10.8yrs	US$343.40k	0.014% $ 3.8m
Eric Topol	Independent Director	15.2yrs	US$346.49k	0.094% $ 25.4m
Nicholas Augustinos	Independent Director	14.8yrs	US$362.21k	0.0092% $ 2.5m
Bridgette Heller	Independent Director	5yrs	US$346.49k	0.0054% $ 1.5m
Kyle Malady	Independent Director	3.9yrs	US$343.40k	0.0039% $ 1.0m
Karen Dahut	Independent Director	4.1yrs	US$345.90k	0.0038% $ 1.0m
Richard Collins	Independent Director	7.5yrs	US$345.90k	0.0098% $ 2.6m
Rimma Driscoll	Independent Director	1.1yrs	US$404.72k	0% $ 0

8.7yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de DXCM sont considérés comme expérimentés (ancienneté moyenne 8.6 ans).

DexCom Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

Executive Chairman recently sold US$4.0m worth of stock

Executive Chairman notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Executive Chairman recently sold US$4.6m worth of stock

Recent updates

DexCom: Investors Discounting Long CGM Growth Runway

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

DexCom, Inc. to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium

Stelo by Dexcom, the First Over-The-Counter Glucose Biosensor in the U.S., Is Now Available

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of DexCom, Inc

DexCom Q2 Earnings: Traditional Market Overreaction

Investor sentiment deteriorates as stock falls 37%

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 41% undervalued after recent price drop

Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

DexCom, Inc. Updates Earnings Guidance for the Year 2024

DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $750 million worth of its shares.

Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

DexCom, Inc. to Report Q2, 2024 Results on Jul 25, 2024

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dexcom Showcases Extensive Clinical Data At ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People with Type 2 Diabetes

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects Directly to Apple Watch in the United States

Dexcom Wins Access to Dexcom One for 100,000 People Living with Type 2 Diabetes

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Now 22% overvalued after recent price rise

Dexcom: Positive Catalysts Ahead To Support Growth

If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

DexCom: Attractive Discount After Strong Earnings Results

DexCom, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

DexCom, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

DexCom, Inc., Annual General Meeting, May 22, 2024

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Now 24% overvalued after recent price rise

DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Executive Chairman recently sold US$4.0m worth of stock

Executive Chairman notifies of intention to sell stock

DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Executive VP notifies of intention to sell stock

DexCom: A Wealth Compounder In Healthcare

Full year 2023 earnings: EPS exceeds analyst expectations

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Executive Chairman recently sold US$4.6m worth of stock

DexCom: Stelo Stellar Outlook

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump

A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

Insufficient new directors

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD

DexCom, Inc. to Report Q3, 2023 Results on Oct 26, 2023

DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

DexCom, Inc Announces the Availability of Its Dexcom One Real-Time CGM Sensor Via Reimbursement, in France

DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023